Replies to post #156324 on Anavex Life Sciences Corp (AVXL)

[F1ash]

Now it actually is an ATM instead of an ELOC.

Anavex Life Sciences Corp.

Up to $50,000,000
Common Stock

We have entered into a Controlled Equity Offering SM Sales Agreement, or Sales Agreement, with Cantor Fitzgerald & Co., or Cantor Fitzgerald, relating to shares of our common stock, par value $.001 per share, offered by this prospectus supplement and accompanying prospectus. In accordance with the terms of the Sales Agreement, we may offer and sell shares of our common stock having an aggregate offering price of up to $50,000,000 from time to time through Cantor Fitzgerald, acting as our sales agent.

Our common stock is currently listed on the Nasdaq Capital Market under the symbol “AVXL”. On July 2, 2018 the last reported sale price of our common stock was $2.66 per share.

Sales of our common stock, if any, under this prospectus will be made by any method that is deemed to be an “at the market offering” as defined in Rule 415(a)(4)under the Securities Act of 1933, as amended, or the Securities Act. Cantor Fitzgerald is not required to sell any specific amount of securities, but will act as our sales agent using commercially reasonable efforts consistent with its normal trading and sales practices, on mutually agreed terms between Cantor Fitzgerald and us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement.

Cantor will be entitled to compensation at a fixed commission rate of 3.0% of the gross proceeds from the sale of our common stock pursuant to the Sales Agreement. In connection with the sale of the common stock on our behalf, Cantor Fitzgerald will be deemed to be an “underwriter” within the meaning of the Securities Act, and the compensation of Cantor Fitzgerald will be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification and contribution to Cantor Fitzgerald against certain civil liabilities, including liabilities under the Securities Act or the Securities Exchange Act of 1934, as amended, or the Exchange Act.

http://secfilings.nasdaq.com/filingFrameset.asp?FilingID=12851983&RcvdDate=7/6/2018&CoName=ANAVEX%20LIFE%20SCIENCES%20CORP.&FormType=424B5&View=html

[Investor2014]

Need to read it carefully, but on a quick scan my thought is that Anavex is replacing LPC with Cantor for the second traunch of $50M and thus this prospectus is for $100M total incorporating the LPC agreement and the sales of stock so far under that agreement.

So no new dilution over what we all are, or should be, aware of thus far.

As I have posted a few times, the LPC and now Cantor agreements are as good as cash and already known, thus Missling can say the company has cash for all planned trial activities.

And btw. it seems the Cantor agreement is even better for Anavex and shareholder than LPC.